# DBC-664 in Adult Patients With Solid Tumors

Source: https://onco.cc/trials/nct07705035/  
OnCo record `nct07705035` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of DBC-664 run by Duboce Biopharmaceuticals, Inc., now recruiting.

## Summary

DBC-664 in Adult Patients With Solid Tumors is a phase 1 interventional study registered as NCT07705035 by Duboce Biopharmaceuticals, Inc., with 210 participants planned, started 2026-07-17. Conditions recorded: Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma, Endometrial Adenocarcinoma and Ovarian Adenocarcinoma. Interventions recorded: DBC-664.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07705035
- Phase: 1
- Setting: A Phase 1a/1b Open Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of DBC-664 in Adult Patients With Locally Advanced or Metastatic Solid Tumors
- Sponsor: Duboce Biopharmaceuticals, Inc.
- Enrolled: 210

## Sources

- ClinicalTrials.gov NCT07705035: https://clinicaltrials.gov/study/NCT07705035

## Connected records

- cancers: [Adenocarcinoma of the lung](https://onco.cc/cancers/lung-adenocarcinoma/), [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [DBC-664](https://onco.cc/drugs/dbc-664/)
- companies: [Duboce Biopharmaceuticals](https://onco.cc/companies/duboce-biopharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct07705035.json